Study of Obizur for adults with acquired hemophilia A in South Korea
Part of Blood & lymphatic clinical trials.
This study is for adults in South Korea with acquired hemophilia A, a rare bleeding disorder. It tests a drug called Obizur to see how well it works for people who need it to control bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acquired hemophilia A.
- Your doctor decides that you need treatment with Obizur.
- You are 18 years old or older.
- You agree to take part and sign a consent form.
- You are not allergic to any part of Obizur.
- You do not have congenital hemophilia A (a different type of hemophilia you are born with).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called Bometase Alfa to help control bleeding in people with acquired hemophilia A, a rare condition where the immune system attacks a clotting protein. If you have active bleeding from this condition, this treatment might help stop it.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
Hear when a new Acquired Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.